medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 4

<< Back Next >>

Med Int Mex 2023; 39 (4)

Pneumothorax associated to non-tuberculous mycobacteria: Mycobacterium abscessus. First case reported in America

Guillén OFC, Palomeque RCA, Guillén NFR

Language: Spanish
References: 22
Page: 713-718
PDF size: 745.29 Kb.


ABSTRACT

Background: In recent years there has been an increase in the incidence of non-tuberculous mycobacterial infections due to new imaging techniques and more advanced cultures, as well as the increase in the immunocompromised population. Within the group of non-tuberculous mycobacteria is Mycobacterium abscessus, which is the most important due to its rapid growth, resistance to treatment with macrolides and for being the main non-tuberculous agent in lung infection. Complications, especially pulmonary ones, are frequent due to its rapid growth and resistance, as well as its chronic evolution.
Clinical case: A patient with a diagnosis of chronic infection by a non-tuberculous mycobacterium, Mycobacterium abscessus, who presented spontaneous pneumothorax as a complication and corresponds to the first report of this type in America.
Conclusions: Pulmonary disease in relation to infectious agents has expanded significantly in recent years, so the initial protocol should be broader and always consider the existence of non-tuberculous mycobacteria, request a culture for Mycobacterium initially, and thus, avoid errors in diagnosis and, above all, delay in treatment.


REFERENCES

  1. González-Martin J. Microbiología de la tuberculosis. SeminFund Esp Reumatol 2017; 15 (1): 25-33.

  2. Palenque E. Skin disease and nontuberculous atypicalmycobacteria. Int J Derm 2001; 39 (9): 659-666. doi:10.1046/j.1365-4362.2000.00821.x.

  3. Mancheno-Valencia M, Arenas-Guzmán R. La infecciónpor micobacterias no tuberculosas, una visión desde laperspectiva dermatológica. Med Cutan Iber Lat Am 2015; 43 (1): 6-13.

  4. Falkinham JO. Epidemiology of Infection by nontuberculousmycobacteria. Clin Microbiol Rev 1996; 9 (2): 177-215. doi:10.1128/cmr.9.2.177.

  5. Horne D, Skerrett S. Recent advances in nontuberculousmycobacterial lung infections. F1000Res 2019; 1-8. doi:10.12688/f1000research.20096.1.

  6. Saleeb P. Pulmonary nontuberculous mycobacterial disease:new insights into risk factors for susceptibility, epidemiology,and approaches to management in immunocompetentand immunocompromised patients. Curr Infect DisRep 2010; 12: 198-203. doi: 10.1007/s11908-010-0103-6.

  7. Contla-Martínez I, Vega-Memije M, Arenas-Guzmán R,Boeta-Ángeles L. Micobacteriosis no tuberculosa porMycobacterium abscessus secundaria a rasguño de gato.Dermatol Rev Mex 2020; 64 (4): 411-417.

  8. Meng-Rui L, Wang-Huei S, Chien-Ching H, Chong-JenY. Mycobacterium abscessus complex infections in humans.Emerg Infect Dis 2015; 21 (9): 1638-1646. doi:10.3201/2109.141634.

  9. Ossés J, Gaitán C, Nahabedian S, Giugno E, et al. Neumotóraxespontáneo primario. Rev Med Resp 2003; 3 (1): 35-49.

  10. Porcel J. Neumotórax espontáneo. Medicina integral 2001;38 (1): 3-7.

  11. Prevots D, Shaw P, Strickland D, Jackson L, et al. Nontuberculousmycobacterial lung disease prevalence at fourintegrated health care delivery systems. Am J Respir CritCare Med 2010; 182: 970-976. doi: 10.1164/rccm.201002-0310OC.

  12. García-Martos, P, García-Agudo, L. Infecciones por micobacteriasde crecimiento rápido. Enferm Infecc MicrobiolClin 2012; 30 (4): 192-200. https://doi.org/10.1016/j.eimc.2011.09.017.

  13. Griffith D, Girard W, Wallace R. Clinical features of pulmonarydisease caused by rapidly growing mycobacteria.An analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271-1278. doi: 10.1164/ajrccm/147.5.1271.

  14. Griffith E, Aksamit T, Brown B, Catanzaro A, et al. An officialATS/IDSA statement: Diagnosis, treatment, and prevention ofnontuberculous Mycobacterial diseases. Am J Respir Crit CareMed 2007; 175: 367-416. doi: 10.1164/rccm.200604-571ST.

  15. Novosad S, Beekmann SE, Polgreen PM, Mackey K, etal. Treatment of Mycobacterium abscessus infection.Emerg Infect Dis 2016; 22 (3): 511-514. doi: 10.3201/eid2203.150828.

  16. Esteban, J, Navas, E. Tratamiento de las infecciones producidaspor micobacterias no tuberculosas. Enferm InfeccMicrobiol Clin 2018; 36 (9): 586-592. DOI: 10.1016/j.eimc.2017.10.008.

  17. Gilbert, D. Guía Sanford de Terapéutica Antimicrobiana.Florida: Medica AWWE. 2019.

  18. Choi W. Pneumothorax. Tuberc Respir Dis 2014; 76: 99-104.doi: 10.4046/trd.2014.76.3.99.

  19. Aktogu S. Clinical spectrum of pulmonary and pleuraltuberculosis: a report of 5,480 cases. Eur Respir J 1996; 9: 2031-2035. doi: 10.1183/09031936.96.09102031.

  20. Ueyama M, Asakura T, Morimoto K, Namkoong H, et al.Pneumothorax associated with nontuberculous mycobacteria.Medicine 2016; 95 (29): 1-9. doi: 10.1097/MD.0000000000004246.

  21. Katano T, Hagiwara E, Arai H, Sato M, Yamaya T, Tajiri M,Ogura T. A case of intrathoracic desmoid tumor with pulmonaryMycobacterium abscessus disease. Respir Med CaseReports 2020; 29: 1-3. doi: 10.1016/j.rmcr.2020.101001.

  22. Kobashi Y, Mouri K, Obsae Y, Kato S, Oka M. Clinical analysisof patients with pulmonary nontuberculous mycobacterialdisease complicated by pneumothorax. Intern Med 2013;52: 2511-2515. doi: 10.2169/internalmedicine.52.0465.




2020     |     www.medigraphic.com